BCAS2 Polyclonal Antibody

BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53- or –mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.

BCAS2; DAM1; Pre-mRNA-splicing factor SPF27; Breast carcinoma-amplified sequence 2; DNA amplified in mammary carcinoma 1 protein; Spliceosome-associated protein SPF 27

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; ELISA 1:5000; Not yet tested in other applications.

BCAS2; DAM1; Pre-mRNA-splicing factor SPF27; Breast carcinoma-amplified sequence 2; DNA amplified in mammary carcinoma 1 protein; Spliceosome-associated protein SPF 27